他莫昔芬治疗女性绝经后晚期乳腺癌50例

50例晚期乳腺癌妇女,比较国产和英制的他莫昔芬(tamoxifen)的疗效,剂量为10mg bid口服,疗程均在3mo(月)以上,随访6mo以上。结果表明激素受体检测可指导内分泌治疗取得较高效应,2种药物无显著差异。该药对乳腺癌疗效较高,毒副作用较低,安全性大,口服使用方便,优于其他内分泌治疗方案,可为绝经后晚期老年乳腺癌妇女首选的激素治疗药物。

Tamoxifen therapy in 50 postmenopausal patients with advanced breast cancer

50 cases of spontaneous or artificial menopausal women, suffered from advanced breast-cancer at stage IV according to UICC system, were treated with tamoxifen from two different sources. Populations of cancer cells, from specimen of each case, should be carefully studied and divided either into hormonal receptor positive(HR + ) or negative (HR- ) according to Lee's fluorescence histochemical method. All of them received tamoxifen 10mg bid for at least three months. By this way most of them could well tolerated without remarkable adverse reaction. Cases with HR+ had a promissing response of 64%, while those of HR-20% only. Our results indicated that there is no difference at all between two sources of drug, and in addition, tomaxifen had definite therapeutic value to combat breast-cancer even with some degree of soft tissue-metastasis but liver and brain have to be excluded.